Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

BACKGROUND: Maintenance therapy with gefitinib notably improves survival in patients with advanced non-small cell lung cancer (NSCLC) and EGFR mutation-positive tumors, but the economic impact of this practice is unclear. METHODS: A decision-analytic model was developed to simulate 21-day patient tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jun, Li, Te, Wang, Xiaohui, Ye, Ming, Cai, Jian, Xu, Yuejuan, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568065/
https://www.ncbi.nlm.nih.gov/pubmed/23360224
http://dx.doi.org/10.1186/1471-2407-13-39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568065/
https://www.ncbi.nlm.nih.gov/pubmed/23360224
http://dx.doi.org/10.1186/1471-2407-13-39

Ejemplares similares